iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.69 Billion KRW | -269.74% |
| 2022 | 5.71 Billion KRW | -41.28% |
| 2021 | 9.72 Billion KRW | -34.92% |
| 2020 | 14.94 Billion KRW | 569.01% |
| 2019 | -3.18 Billion KRW | -136.59% |
| 2018 | 8.71 Billion KRW | 199.73% |
| 2017 | -8.73 Billion KRW | -1330.94% |
| 2016 | -610.37 Million KRW | -139.18% |
| 2015 | 1.55 Billion KRW | 0.0% |
| 2012 | -1.18 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -375.81 Million KRW | 89.85% |
| 2024 Q2 | 579.25 Million KRW | 254.13% |
| 2023 FY | -9.69 Billion KRW | -269.74% |
| 2023 Q3 | -2.59 Billion KRW | -40.31% |
| 2023 Q4 | -3.7 Billion KRW | -42.86% |
| 2023 Q2 | -1.84 Billion KRW | -18.92% |
| 2023 Q1 | -1.55 Billion KRW | 56.46% |
| 2022 Q3 | -1.68 Billion KRW | -113.83% |
| 2022 FY | 5.71 Billion KRW | -41.28% |
| 2022 Q4 | -3.56 Billion KRW | -111.89% |
| 2022 Q2 | 12.17 Billion KRW | 1103.54% |
| 2022 Q1 | -1.21 Billion KRW | -147.56% |
| 2021 Q1 | 1.36 Billion KRW | -65.48% |
| 2021 FY | 9.72 Billion KRW | -34.92% |
| 2021 Q4 | 2.55 Billion KRW | 11.17% |
| 2021 Q2 | 3.51 Billion KRW | 157.49% |
| 2021 Q3 | 2.29 Billion KRW | -34.75% |
| 2020 Q3 | 2 Billion KRW | -78.98% |
| 2020 FY | 14.94 Billion KRW | 569.01% |
| 2020 Q4 | 3.95 Billion KRW | 96.93% |
| 2020 Q1 | -572.45 Million KRW | 82.73% |
| 2020 Q2 | 9.55 Billion KRW | 1769.21% |
| 2019 FY | -3.18 Billion KRW | -136.59% |
| 2019 Q4 | -3.31 Billion KRW | -20.38% |
| 2019 Q3 | -2.75 Billion KRW | -184.87% |
| 2019 Q2 | 3.24 Billion KRW | 993.42% |
| 2019 Q1 | -363.14 Million KRW | -103.38% |
| 2018 FY | 8.71 Billion KRW | 199.73% |
| 2018 Q2 | 3.71 Billion KRW | 367.0% |
| 2018 Q1 | -1.39 Billion KRW | 72.06% |
| 2018 Q3 | -4.36 Billion KRW | -217.39% |
| 2018 Q4 | 10.74 Billion KRW | 346.42% |
| 2017 Q1 | -70.08 Million KRW | 95.38% |
| 2017 FY | -8.73 Billion KRW | -1330.94% |
| 2017 Q4 | -4.98 Billion KRW | -2547.36% |
| 2017 Q3 | -188.12 Million KRW | 94.62% |
| 2017 Q2 | -3.49 Billion KRW | -4887.51% |
| 2016 FY | -610.37 Million KRW | -139.18% |
| 2016 Q4 | -1.51 Billion KRW | -315.51% |
| 2016 Q3 | -365.06 Million KRW | -88.65% |
| 2016 Q2 | -193.51 Million KRW | -9.68% |
| 2016 Q1 | -176.43 Million KRW | 0.0% |
| 2015 FY | 1.55 Billion KRW | 0.0% |
| 2013 Q3 | 37.45 Million KRW | 10.7% |
| 2013 Q2 | 33.83 Million KRW | -84.74% |
| 2013 Q1 | 221.68 Million KRW | 218.87% |
| 2012 FY | -1.18 Billion KRW | 0.0% |
| 2012 Q4 | -186.49 Million KRW | 35.66% |
| 2012 Q3 | -289.86 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 94.872% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 307.577% |
| Bioneer Corporation | -10.58 Billion KRW | 8.422% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -241.286% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 266.017% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 80.183% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 84.872% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -14.994% |
| Medy-Tox Inc. | 9.75 Billion KRW | 199.388% |
| Peptron, Inc. | -15.92 Billion KRW | 39.106% |
| Amicogen, Inc. | -23.28 Billion KRW | 58.369% |
| Genexine, Inc. | -66.87 Billion KRW | 85.502% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -321.144% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 86.845% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -187.547% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 112.665% |
| SillaJen, Inc. | -20.36 Billion KRW | 52.402% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 169.422% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 49.243% |
| Genomictree Inc. | -8.75 Billion KRW | -10.728% |
| MedPacto, Inc. | -35.32 Billion KRW | 72.554% |
| D&D Pharmatech | 3.93 Billion KRW | 346.464% |
| EASY BIO,Inc. | 15.54 Billion KRW | 162.375% |
| GI Innovation, Inc. | -55.49 Billion KRW | 82.529% |